SEC Form 4 · accession 0001572426-16-000158
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Damian T. Lismore
Officer — Chief Financial Officer
Period of report
Feb 18, 2016
Accepted (ET)
Feb 22, 2016 · 7:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Feb 18, 2016 | P | 5,000 | $3.2199 | A | 18,724 | I | Glenariff Superannuation Pty Ltd <Glenariff Super Fund A/C> |
| Ordinary Shares | holding | — | — | — | 16,000 | D | ||
| Ordinary Shares | holding | — | — | — | 14,160 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.19 to $3.29, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F2The reporting person and his spouse share voting and dispositive power with respect to these reported securities.